MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsQuality SystemClinical EvidenceRWE

    Real-World Evidence

    Clinical evidence regarding the usage and potential benefits or risks of a device derived from real-world data.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    RWE is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data (RWD), including EHRs, registries, and claims.
    What the regulation says
    The FDA issues guidance on the use of Real-World Evidence (RWE) to support regulatory decision-making for medical devices, as outlined in their "Real-World Evidence Guidance for Medical Devices" document. This guidance details considerations for relevance and reliability of Real-World Data (RWD) sources, aligning with principles for valid scientific evidence. The EU Medical Device Regulation (EU MDR) also acknowledges the value of RWE, particularly for post-market surveillance (PMS) and substantiating clinical benefits and safety in the post-market phase, as described in Annex III, section 1.1(f) regarding clinical evaluation.

    What this means in practice

    FDA accepts RWE to support regulatory decisions when relevance and reliability are demonstrated. RWE is increasingly important for AI/ML monitoring and PMS.

    Examples

    • A medical device manufacturer uses RWE from a national patient registry to demonstrate the long-term safety and effectiveness of their implanted cardiac device in a diverse patient population.
    • An AI-powered diagnostic software company utilizes RWE from de-identified electronic health records to support the clinical validity and utility of their algorithm for early disease detection.
    • A pharmaceutical company submits RWE derived from insurance claims data to support a new indication for an approved drug, showing its effectiveness in a real-world setting outside of a controlled trial.
    Common pitfalls
    • •RWE derived from unreliable or biased RWD sources may not be accepted by regulatory authorities, leading to delays or rejection of submissions.
    • •Failure to adequately document RWD collection methods and RWE analysis plans can undermine the credibility of the evidence.
    • •Generalizing RWE from one population to another without proper justification is a common pitfall.
    • •Ignoring potential confounding factors in RWD can lead to inaccurate conclusions about a medical product's performance.
    • •Using RWE for indications not supported by the data's scope or context will be viewed critically by regulators, such as the FDA.

    Frequently asked questions

    RWE is derived from data collected in routine clinical practice or real-world settings, offering insights into product performance in a broader patient population and under typical usage conditions. Traditional clinical trials, conversely, are typically conducted in highly controlled environments with specific inclusion and exclusion criteria.

    Cross-references

    See also

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Learning paths (2)

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·1ICH·1ISO·1
    1. 1
      FDA RWE Framework
      Verified
      FDAfda.gov
    2. 2
      ICH Guidelines
      Verified
      ICHich.org
    3. 3
      ISO 14155 Standard Page
      Verified
      ISOiso.org

    Inline markers like [1] jump to the matching reference above.